Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in
randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard
anticoagulants in the predefined subgroup of children with cerebral venous thrombosis
(CVT) who participated in the EINSTEIN-Jr trial. Children with CVT were randomized (2: 1),
after initial heparinization, to treatment with rivaroxaban or standard anticoagulants
(continued on heparin or switched to vitamin K antagonist). The main treatment period was 3 …